Platform Trial For Cryptococcal Meningitis (PLATFORM-CM) (PLATFORM-CM)

July 23, 2026 updated by: David Boulware

Platform Trial For Cryptococcal Meningitis

Cryptococcal meningitis is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal therapy, mortality rates remain high, especially in low and middle income countries where the ongoing HIV/AIDS pandemic increases the risk of cryptococcosis among persons living with HIV infection. The combination of amphotericin and flucytosine (5-FC) has been the mainstay of therapy for the initial management of cryptococcal meningitis for 4 decades. Indeed, the effective delivery of these first line therapy in Africa can lower mortality to 25%. However, several challenges exist. First, even while 5-FC is included on the WHO list of essential medicines, the availability of 5-FC worldwide is limited. Second, liposomal amphotericin (Ambisome ®) is currently available from a single source supplier, creating risk. Third, current therapies have substantial toxicity. Lastly, with widespread agricultural fungicide use of azoles, the median fluconazole minimum inhibitory concentration (MIC50 ) for Cryptococcus has doubled since 2013. Globally, new or improved antifungals are needed for cryptococcal meningitis, particularly those which have less toxicity, greater efficacy, a prolonged half-life, and minimal drug-drug interactions.

As multiple new antifungal medicines are on the horizon, this platform trial utilizes a master protocol to investigate, multiple antifungal regimens using standardized eligibility criteria, standardized study schedule of events, and standardized contemporary endpoints.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

2000

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Kampala, Uganda
      • Mbarara, Uganda
        • Recruiting
        • Mbarara University of Science and Technology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • CSF cryptococcal antigen (CrAg) positive meningitis
  • Living with HIV
  • Ability and willingness to provide informed consent
  • Willing to receive protocol-specified lumbar punctures
  • Age >= 18 years
  • Female participants of childbearing potential who are participating in sexual activity that could lead to pregnancy must agree to use reliable forms of contraception (duration will be indicated in each Trial Appendix).

Exclusion Criteria:

  • Received 3 or more doses of antifungal therapy for meningitis within last 30 days
  • Inability to take enteral (oral or nasogastric) medicine
  • Cannot or unlikely to attend regular clinic visits
  • Receiving chemotherapy or corticosteroids
  • Receiving hemodialysis or known liver cirrhosis
  • Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)
  • Pregnancy or breastfeeding
  • Previous administration of investigational study drug
  • Any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments
  • Trial Appendix study-drug specific eligibility criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
randomized to standard of care

2022 WHO First Line Induction Therapy:

  1. Liposomal Amphotericin B 10mg/kg IV given once
  2. Flucytosine 100mg/kg/day for 14 days in divided doses
  3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum
Experimental: Experimental group 1
randomized to experimental antifungal therapy #1

Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)

  • Loading doses of oral Oteseconazole 600 mg twice daily for 10 days, then 600 mg oteseconazole weekly on weeks 3, 4, 5, and 6.
  • Liposomal Amphotericin B 10 mg/kg IV once.
  • No fluconazole or 5FC to be given.
Experimental: Experimental group 2
randomized to experimental antifungal therapy #2
SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 with Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
Experimental: Experimental group 3
randomized to experimental antifungal therapy #3
SF001 3.0 mg/kg IV administered on day 1, 8, and 15 with fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
Experimental: Experimental group 4
randomized to experimental antifungal therapy #4
Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51) ● Loading doses of oral Oteseconazole 600 mg twice daily for 12 days, then 600 mg oteseconazole weekly on weeks 3 to 12. ● Liposomal Amphotericin B 10 mg/kg IV once. ● Flucytosine 100mg/kg given for 7 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of cerebrospinal fluid (CSF) Cryptococcus clearance (Early Fungicidal Activity, or EFA)
Time Frame: 2 weeks
quantified by the change of log 10 Cryptococcus CFU/mL CSF/day as measured by serial quantitative CSF fungal cultures over ~2 weeks.
2 weeks
All-cause mortality
Time Frame: 2 weeks
measured at 2-weeks
2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
18-week survival time
Time Frame: 18 weeks
18 weeks
Desirability of Outcome Response (DOOR) as ordinal ranked maximum score tested by Win Ratio.
Time Frame: 18 weeks
  1. Death by 18-weeks
  2. Serious Adverse Event through 18 weeks (e.g. all-cause re- hospitalization, permanent neurologic deficit, etc.), lost to follow up before 10-weeks.
  3. Grade 4 lab adverse event by 10 weeks, early discontinuation of study drug, or lost to follow up after 10 weeks.
  4. Grade 3 lab adverse event by 10 weeks OR study drug interruption or dose reduction
  5. Survival through 18-weeks
18 weeks
Survival time through 18 weeks without Cryptococcus culture-positive relapse of meningitis
Time Frame: 18 weeks
number of participants
18 weeks
CSF culture sterility (cumulative incidence over 18 weeks)
Time Frame: 18 weeks
18 weeks
Use of rescue/additional IV amphotericin beyond scheduled use
Time Frame: 18 weeks
18 weeks
Modified Rankin score on functional status at 18 weeks
Time Frame: 18 weeks
18 weeks
Incidence of laboratory abnormalities by Grade 1-5
Time Frame: 10 weeks
10 weeks
Incidence of serious adverse events
Time Frame: 18 weeks
18 weeks
Incidence of study drug discontinuation or interruption >1 day due to toxicity, by adverse event grade.
Time Frame: 10 weeks
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: David R Boulware, MD, MPH, University of Minnesota
  • Principal Investigator: David B Meya, MBChB, MMed, PhD, Uganda

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 28, 2025

Primary Completion (Estimated)

April 21, 2032

Study Completion (Estimated)

April 21, 2032

Study Registration Dates

First Submitted

October 29, 2024

First Submitted That Met QC Criteria

October 29, 2024

First Posted (Actual)

October 30, 2024

Study Record Updates

Last Update Posted (Actual)

July 27, 2026

Last Update Submitted That Met QC Criteria

July 23, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified dataset will be shared after publication in accordance with ICJME standards.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe